Search results
Results from the WOW.Com Content Network
Financials as of September 30, 2023. [update] [1] Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company and a contract research organization that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. [2]
AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Let's see if AmerisourceBergen Corporation (ABC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
AmerisourceBergen now expects 2023 adjusted earnings in the range of $11.85 to $11.95 per share, compared with its prior forecast of $11.70 to $11.90 per share.
For premium support please call: 800-290-4726 more ways to reach us
AmerisourceBergen (ABC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Steven H. Collis (born 1961) is an American businessman, the chairman, president and chief executive officer (CEO) of Cencora, previously known as AmerisourceBergen. Early life. Collis was born in South Africa and attended the University of Witwatersrand, where he earned a Bachelor of Commerce. Collis is Jewish. Career